Gershon Capital & Cie

Gershon Capital is a Swiss early stage healthcare private equity and healthcare investment advisory firm that provides a full suite of transatlantic financial and strategic solutions for emerging life science companies.

The firm is a team of 32 people that provides direct investment, grants, equity and debt financing, and M&A advisory for early stage life science companies.

We work with the highest quality companies and syndicate deals to the most prominent institutional investors in Europe, the Middle East, Asia, and the U.S. alongside our direct investment.

Medical, Legal, Regulatory & Operational Expertise

We leverage 20 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our strategy and gives investors  a high level of confidence that companies we work with will be successful.

Strong Relationships & Professional Networks

Our long standing relationships and professional affiliations with many of the most respected institutional investment funds, academic centers and industry leaders allows us to provide high level strategic consulting, technical advisory services, and deal syndication.

Vertically Integrated Partnerships

Our strong partnership with several prominent investment banks make us a fully vertically integrated investment firm, offering a broad array of capital raising solutions and financial advisory services for healthcare and life sciences companies.

Global Access to Capital and Financing

We believe that global access to capital and financing is critical for our clients and counterparties who are looking for efficient private placement, licensing, royalty monetization, and M&A transactions. Our headquarters are in Geneve and New York, with affiliate offices in Zurich, London, Tel Aviv, and Beijing. And our integrated networks throughout these geographies allows us to access over 3000 institutional, strategic, and high net worth investors and family funds.